Beam's Base Editor Advances to Pivotal Development on Back of Impressive AATD Data on March 27, 2026 alpha 1-Antitrypsin Deficiency Base Editing Beam Therapeutics BEAM-302 development aspects Phase 1/2 data +
FDA Rejects UniQure's AMT-130 Gene Therapy Data for Huntington's, Demands New Sham-Controlled Trial on March 06, 2026 AMT-130 gene therapy Huntington 's disease Phase 1/2 data sham-controlled trial uniQure United States Food and Drug Administration +
Nuvalent Shares Positive Phase 1/2 ALK Inhibitor Data Rivaling Pfizer’s Lorbrena in Lung Cancer on November 17, 2025 ALK Inhibitor ALKOVE-1 trial Clinical Trials CNS activity Frequency of Responses Lorbrena lorlatinib neladalkib Non-Small Cell Lung Carcinoma Nuvalent Phase 1/2 data United States Food and Drug Administration +